In prior studies, CREMα has been identified as a central factor in the T cell pathogenesis of SLE by inhibition of IL-2, induction of IL-17a expression, and enhancement in numbers of pathogenic DN T cells. Here, IL2 is linked to systemic lupus erythematosus.